Definium Therapeutics (NASDAQ: DFTX) has dosed the first patient in Ascend, its second phase 3 study evaluating DT120 ODT for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE